医中誌リンクサービス


文献リスト

1)Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015; 386: 1546-55
PubMed CrossRef
医中誌リンクサービス
2)Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization 2015. 2015 Mar
医中誌リンクサービス
3)日本肝臓学会.B型肝炎治療ガイドライン Ver. 2.1. 日本肝臓学会; 2015
医中誌リンクサービス
4)Lampertico P, Maini M, Papatheodoridis G. Optimal Management of Hepatitis B Virus Infection - EASL Special Conference. J Hepatol. 2015. [Epub ahead of print]
医中誌リンクサービス
5)Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (Baltimore, Md). 2010; 52: 886-93
医中誌リンクサービス
6)Kumada T, Toyoda H, Tada T, et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol. 2013; 58: 427-33
PubMed CrossRef
医中誌リンクサービス
7)Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology (Baltimore, Md). 2013; 58: 98-107
医中誌リンクサービス
8)Wong GL, Chan HL, Chan HY, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology. 2013; 144: 933-44
医中誌リンクサービス
9)Arends P, Sonneveld MJ, Zoutendijk R, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. 2015; 64: 1289-95
PubMed CrossRef
医中誌リンクサービス
10)Wong VW, Janssen HL. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol. 2015. [Epub ahead of print]
医中誌リンクサービス
11)Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013; 381: 468-75
PubMed CrossRef
医中誌リンクサービス
12)Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology (Baltimore, Md). 2014; 59: 434-42
医中誌リンクサービス
13)Chan HL, Chan CK, Hui AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology. 2014; 146: 1240-8
医中誌リンクサービス
14)Marcellin P, Buti M, Krastev Z, et al. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol. 2014; 61: 1228-37
PubMed CrossRef
医中誌リンクサービス
15)Lim YS, Yoo BC, Byun KS, et al. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 2015. [Epub ahead of print]
医中誌リンクサービス
16)Belloni L, Allweiss L, Guerrieri F, et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012; 122: 529-37
PubMed CrossRef
医中誌リンクサービス
17)Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014; 343: 1221-8
PubMed CrossRef
医中誌リンクサービス
18)Zoulim F, Carosi G, Greenbloom S, et al. Quantification of HBsAg in nucleos(t)ide-naive patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. J Hepatol. 2015; 62: 56-63
PubMed CrossRef
医中誌リンクサービス
19)Kennedy EM, Bassit LC, Mueller H, et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology. 2015; 476: 196-205
PubMed CrossRef
医中誌リンクサービス
20)Lin SR, Yang HC, Kuo YT, et al. The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids. 2014; 3: e186
PubMed
医中誌リンクサービス
21)Ramanan V, Shlomai A, Cox DB, et al. CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep. 2015; 5: 10833
PubMed
医中誌リンクサービス
22)Weber ND, Stone D, Sedlak RH, et al. AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PloS One. 2014; 9: e97579
CrossRef
医中誌リンクサービス
23)Chen Y, Hu W, Lu Y, et al. A TALEN-based specific transcript knock-down of PIWIL2 suppresses cell growth in HepG2 tumor cell. Cell Prolif. 2014; 47: 448-56
PubMed CrossRef
医中誌リンクサービス
24)Menne S, Tumas DB, Liu KH, et al. Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B. J Hepatol. 2015; 62: 1237-45
PubMed CrossRef
医中誌リンクサービス
25)Gane EJ, Lim YS, Gordon SC, et al. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. J Hepatol. 2015; 63: 320-8
PubMed CrossRef
医中誌リンクサービス
26)Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015; 148: 215-9; quiz e16-7
医中誌リンクサービス
27)Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology (Baltimore, Md). 2014; 59: 2092-100
医中誌リンクサービス
28)Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of Hepatitis B Virus (HBV) DNA and Risk of HBV Reactivation in B-Cell Lymphoma: A Prospective Observational Study. Clin Infect Dis. 2015. [Epub ahead of print]
医中誌リンクサービス
29)Chen CL, Yang JY, Lin SF, et al. Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan. J Hepatol. 2015; 63: 354-63
PubMed CrossRef
医中誌リンクサービス
30)Ito K, Yotsuyanagi H, Yatsuhashi H, et al. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology (Baltimore, Md). 2014; 59: 89-97
医中誌リンクサービス
31)Ito K, Yotsuyanagi H, Sugiyama M, et al. Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan. J Gastroenterol Hepatol. 2015. [Epub ahead of print]
医中誌リンクサービス
32)厚生科学研究費補助金 肝炎等克服政策研究事業.「小児におけるB型肝炎の水平感染の実態把握とワクチン戦略の再構築に関する研究」結果概要(須磨崎亮主任研究者).第12回 予防接種基本方針部会(平成27年1月9日)資料
医中誌リンクサービス


NPO医学中央雑誌刊行会
https://www.jamas.or.jp/
info@jamas.or.jp